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Due to the dynamic development of molecular neurobiology and bioinformatic methods several novel 
brain neuropeptides have been identified and characterized in recent years. Contemporary techniques 
of selective molecular detection e.g. in situ Real-Time PCR, microdiffusion and some bioinformatics 
strategies that base on searching for single structural features common to diverse neuropeptides such 
as hidden Markov model (HMM) have been successfully introduced. A convincing majority of 
neuropeptides have unique properties as well as a broad spectrum of physiological activity in 
numerous neuronal pathways including the hypothalamus and limbic system. The newly discovered 
but uncharacterized regulatory factors nesfatin-1, phoenixin, spexin and kisspeptin have the potential 
to be unique modulators of stress responses and eating behaviour. Accumulating basic studies revelaed 
an intriguing role of these neuropeptides in the brain pathways involved in the pathogenesis of anxiety 
behaviour. Nesfatin-1, phoenixin, spexin and kisspeptin may also distinctly affect the energy 
homeostasis and modulate food intake not only at the level of hypothalamic centres. Moreover, in 
patients suffered from anxiety and anorexia nervosa a significant, sex-related changes in the plasma 
neuropeptide levels occurred. It should be therefore taken into account that the targeted 
pharmacomodulation of central peptidergic signaling may be potentially helpful in the future treatment 
of certain neuropsychiatric and metabolic disorders. This article reviews recent evidence dealing with 
the hypothetical role of these new factors in the anxiety-related circuits and pathophysiology of 
anorexia nervosa.  
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Anxiety and eating disorders are commonplace, persistent severe psychiatric 
impairments with poor prognosis. It is generally accepted that anxiety disorders are at 
present the most prevalent of psychiatric conditions (Stein et al. 2017). Importantly, a 
high comorbidity between anxiety and broadly defined depression disorders occurs 
throghout the population (Thibaut 2017). Anorexia nervosa (AN) is a relatively 
common disorder that affects mainly adolescent and young adult women, the 
male/female ratio in AN is one to five (female 83.5% vs male 16.5%),  and is 
characterized by restriction of food intake relative to energy needs, anxious 
behaviour coupled with seriously distorted body image. Many patients with AN 
unfortunately deny the seriousness of their life-threatening conditions and 
standarized mortality ratio may reach 18%. (Klump et al. 2009).  
Currently, there are numerous presumptions that postulate the existence of a 
relationship between anxiety/AN pathogenesis and disturbances in brain peptidergic 
circuits (Cuesto et al. 2017, Gorwood et al. 2016, Yoshimura et al. 2015). Despite the 
accumulating number of neurochemical studies, there is still insufficient evidence 
dealing with the influence of central peptidergic signaling on the course of anxiety 
and eating disorders. Furthermore, there is no coherent model clarifying the origin of 
these disturbances at the level of hypothalamic and extrahypothalamic regulatory 
factors and their receptors. Moreover, a fully translational experimental animal 
paradigm of AN is currently lacking. Recently  significant progress has been made in 
the mechanisms and purpose of the hypothalamic regulation of food intake and 
energy balance. The functional description of intercellular interactions within the 
hypothalamic nuclei has recently been defined, with novel neuronal populations 
characterized and new multifunctional brain neuropeptides discovered (Stengel and 
Tache 2010, Yosten at. al. 2013, Porzionato et al. 2010, Fu et al. 2010). 
Nonetheless, the number of papers concerning the newly discovered brain regulatory 
factors nesfatin-1, phoenixin, spexin and kisspeptin in the context of anxiety and AN 
pathogenesis remains scarce. This review is focused on providing a comprehensive 




2. Neuropeptides in the pathogenesis of anxiety  
 
Neuropeptides have long been implicated in the regulation of anxiety. The 
corticotropin-releasing factor (CRF) family, comprised of CRF and urocortins (Ucn)1, 
2, and 3, is a key component of the hypothalamo-pituitary-adrenal (HPA) axis, a 
system critical for stress responsivity (Kormos and Gaszner 2013). CRF acts at the 
anterior pituitary to stimulate the release of adrenocorticotropic releasing hormone 
(ACTH), which ultimately induces glucocorticoid synthesis and release from the 
adrenal glands (Rivier et al. 1982).To date, Ucn’s effects on the HPA axis are not  
well defined. However, UcnI may augment HPA axis activity by stimulating CRF 
synthesis (Bagosi et al. 2014), while UcnII and III appear to dose-dependently either 
stimulate or inhibit CRF (Bagosi et al. 2013).The CRF family binds to two known 
receptors, CRFR1 and CRFR2. While CRF has a much higher affinity for CRFR1, 
UcnI appears equally selective for both receptors, and UcnII and III act almost 
exclusively through CRFR2 (Brar et al. 2004). Interstingly, anxiety-like behavior is 
decreased in mice lacking CRFR1 (Smith et al. 1998), suggesting an anxiogenic role 
for this receptor subtype. This anxiogenic-like effect of CRFR1 has been reported by 
a number of groups (Bale et al. 2004), although this effect may be dependent on 
brain region (Sztainberg et al. 2011). In contrast, CRFR2 deficient mice show an 
elevation in anxiety-like behavior and an increase in stress sensitivity (Bale et al. 
2000, Chotiwat et al. 2010). However, the nature of CRFR2’s effects on anxiety is 
region-dependent, as this receptor serves an anxiogenic-like role in the medial 
amygdala (Alves et al. 2016) and lateral septum (Anthony et al. 2014), but appears to 
have an anxiolytic-like function in the ventromedial hypothalamus (Silva et al. 2017) . 
Thus, although CRFR1 and CRFR2 may function in opposition to one another, the 
effects of these receptors on anxiety are likely to be region-specific. Two additional 
neuropeptides, oxytocin (OT) and arginine vasopressin (AVP), are well known 
regulators of anxiety and stress responsivity, acting both on the HPA axis and 
through independent mechanisms. AVP acts synergistically with CRF to enhance 
ACTH release from the pituitary (Knepel et al.1984). OT’s effects on HPA axis 
activation appear largely site-dependent, as OT inhibits CRF synthesis within the 
paraventricular nucleus (Jurek et al. 2015), yet augments ACTH release in response 
to CRF at the level of the pituitary (Gibbs et al. 1984). The AVP-deficient Brattleboro 
rat exhibits mildly decreased anxiety-like behavior (Fodor et al. 2016) supporting a 
potentially anxiogenic effect of this hormone. Similarly, mice lacking the AVP receptor 
V1a (Bielsky et al. 2004) and rats treated with a V1a antagonist (Bleickardt et al. 
2009) show reduced anxiety-like behavior, while intracerebroventricular injection of 
AVP increases anxiety-like behavior in the rat (Bhattacharya et al. 1998). Despite 
substantial genetic homology between OT and AVP, OT largely shows a very 
different effect on anxiety. Female OT knockout mice have a more anxiety-like 
behavioral profile than controls (Mantella et al. 2003), and OT generally has an 
anxiolytic-like effect when administered either centrally (Sabihi et al. 2017) or 
peripherally (Ayers et al. 2011). While AVP and OT have a clear influence on anxiety, 
through HPA axis activation and inhibition respectively, these neuropeptides also 
mediate anxiety-like behavior through projections from the paraventricular nucleus to 
distal regions such as the central nucleus of the amygdala. Perhaps unsurprisingly, 
activation of OT receptors in this region decreases anxiety-like behavior (Knobloch et 
al. 2012), while V1a receptor activation has an anxiogenic-like effect (Hernandez et 
al. 2016), providing further support for oppositional roles for these hormones. 
Neuropeptide S (NPS), a brainstem multifunctional regulatory factor,  seems to be 
another important player in the mechanism of anxiety (Slattery et al. 2015, Wegener 
et. al. 2012). Behavioural studies show that NPS administration has a strong 
dopamine-related anxiolytic effect in rats. (Lukas et al. 2012). Moreover after NPS 
injection into the mouse amygdala a decrease of conditioned fear occurs (Jungling et 
al. 2008). Some clinical trials also suggest, that NPSR gene variations could be 
connected with stress reaction and increased HPA axis stimulation (Kumsta et al. 
2013).  Orexins (hypocretins) may also play an important role in the pathogenesis of 
anxiety (Flores et al. 2015). Orexins A and B have a strong and preservedstructural 
homology in many species of incretin family neuropeptides. Orexin A is built of 33 
amino acids with 2 disulphide bonds and has a higher stability in the cerebrospinal 
liquid and serum than orexin B. Orexin B is in turn a linear molecule composed of 28 
amino acids but  its concentration in the brain is 2-5 times higher in comparison to 
orexin A (Peyron and Kilduff 2017, Sakurai et al., 1998). Orexins are the ligands of 
two metabotropic receptors OX1R and OX2R with diverse affinity to orexin isoforms; 
OX1R has higher affinity to orexin A, whereas OX2R is equally sensitive to both 
molecules (Kukkonen 2013). The anatomical distribution of orexin neurons in both 
the human and animal brain are limited almost exclusively to the lateral 
hypothalamus (Sakurai et al., 1998). Patients suffering from panic attacks showed 
elevated level of OXs in cerebrospinal fluid in comparison with healthy controls 
(Johnson et al. 2010). A new finding indicates that extended stress may increase the 
number of orexin A expressing neurons in the male mouse hypothalamus (Jalewa et 
al. 2014). In rats exposed to particular volatile stressors, such as predator odour, the 
inhibition of orexin receptor OX1R via selective antagonist SB-334867, resulted in 
decreased c-Fos expression in the hypothalamus (Vanderhaven et al. 2015). 
 On the other hand a recent elegant study utilizing DREADDs technique, suggests 
that OX2R may be involved in the generation of acute stress responses in male rats 
and it may depress the habituation to repeated stress under high level of orexins 
(Grafe et al. 2017). 
 
3. Neuropeptides in the mechanisms of anorexia nervosa 
 
A hypothesis that anorexia nervosa is a result of extended stimulation of reward 
circuits by hypothalamic orexigenic neuropeptides seems to be best documented and 
widely accepted (Gorwood et al. 2016, Aston-Jones et al. 2010). In patients with AN 
ghrelin, orexins and 26RFa expressions are generally upregulated reflecting a 
homeostatic mechanism to stimulate eating behaviour and to minimize severe 
malnutrition. Nevertheless in AN this regulatory pathway may be strongly impaired 
and insufficient allowing patients’ brains to resist numerous orexigenic factors. There 
is also an alternative point of view speculating that extended increases of  orexin, 
MCH and 26RFa neuronal activity in the lateral hypothalamus reinforce  food 
aversion by stimulation of dopamine-dependent anxiety in brain reward circuits. 
Interestingly patients in remission from AN maintain an elevated response to food 
stimuli in the reward centres (Cowdrey et al. 2011), that supports the postulate that 
AN is a result of an incorrectly augmented reward process for pathologically 
restricted food intake. In the animal model, fasting causes up-regulation of orexin 
prohormone prepro-orexin (PPOX) at the transcriptional level whereas in obese mice 
a decreased  PPOX gene expression occurs (Sakurai et al. 1998). Conversely, 
insufficient orexin signaling in mice strongly suppresses food intake (Hara et al. 
2001).  There are two parallel studies dealing with the changes in the orexin 
concentration in the plasma of patients suffering from AN. The first finding preformed 
by Janas-Kozik et al. (2011) revealed a decreased level of OxA in untreated females 
with AN, the second showed in turn an increase of the neuropeptide level under the 
same clinical condition (Bronsky et al. 2011). Despite this discrepancy, both the 
authors reported a decrease in the OxA level during refeeding that may indicate up-
regulation of orexinergic signaling in AN. Interestingly, during realimentation of the 
AN patients, ghrelin seemed to have the same mode of changes as orexin (Janas-
Kozik et al. 2007). It should be underlined that plasma neuropeptide concentration 
does not a direct reflection of secretory changes that take place in the hypothalamus. 
On the other hand, the conflicting results may in some way support the mixed-signal 
hypothesis of AN (Inui et al. 2001). Orexin neurons seem to play a distinct role in the 
reward-related aspects of feeding behaviour, their activation being strictly connected 
with food or drug reward (Harris et al. 2005). Central infusion of orexin increases 
sugar uptake in rats (Cason et al. 2010), but its targeted injection to the ventral 
tegmental area (VTA) stimulates the synaptic endings of the local neurons to release 
dopamine to the nucleus accumbens that reinforce consumatory activity (Zheng et al. 
2007). An OX1R antagonist abolished these effects in satiated rats (Gorwood et al. 
2016). Melanin concentrating hormone (MCH) is the next well known strongly 
orexigenic neuropeptide with an abundant expression in the lateral hypothalamus 
(Della-Zuana et al. 2012). Intracerebroventricular MCH administration causes 
significant increase of food intake in rats by stimulation of two metabotropic receptor 
MCHR1 (Forray et al. 2003). Importantly, MCH is considered to be involved in 
orexigenic signaling at the level of reward circuits, especially in the nucleus 
accumbens (NAc). After targeted injections of MCH antagonists into the rat NAc a 
distinct decrease in food consumption occurs (Georgescu et al. 2005). It may suggest 
a potential not yet investigated role of MCH in the molecular event underlying AN. 
Both lateral and vetromedial hypothalamus house recently described group of 
26RFa-expressing neurons (Chartrel et al. 2016). The 26RFa (QRFP) is another 
orexigenic neuropeptide, a ligand of the metabotropic GPR103(QRFPR) receptor 
(Takayasu et al. 2006). The GBP103 expressing cells are also located outside the 
hypothalamus, in the structures that form reward systems such as VTA, amygdala 
and NAc (Bruzzone et al. 2007). Intracerebrovenricular injection of 26RFa strongly 
promotes eating behaviour in rats (Moriya et al. 2006). Expression of the 26RFa gene 
may be regulated by the disturbances of energy expenditure, for instance in the 
hypothalamus obese ob/ob mice 26RFa levels are up-regulated (Takayasu et al. 
2006). An interesting chronobiological study by Galusca et al. (2012) show that 
females with restrictive AN had increased plasma 26RFa levels over the day in 
comparison with controls. Oxytocin is also a potent anorexigenic factor that 
suppresses food intake probably through inhibition of reward signaling pathways 
(Blevins et al. 2015, Herisson et al. 2014). Noteworthy, in females with AN the 
intensity of anxiety, depression and eating restrictions is positively correlated with 
serum oxytocin levels measured after meals (Lawson et al. 2013). On the other hand 
it was also recently suggested that impairment of oxytocin pathways may contribute 
to persistent anxiety and depressive symptoms after partial weight recovery from AN 
(Afinogenova et al. 2016) 
 
4. Nesfatin-1 in anxiety and eating disorders 
4.1. Overview 
Nesfatin-1, an 82-amino acid molecule is composed of 3 domains: N-terminal (N23), 
middle (M30) and C-terminal (C29). The M30 domain appears to play a crucial role in 
induction of physiological mainly anorexigenic effects of this neuropeptide (Atsuchi et 
al. 2010, Oh-I et al. 2006, Fig.1.). Nesfatin-1 is secreted after post-translational 
cleavage from the precursor NEFA/nucleobindin-2 (NUCB2), due to specific 
convertase PC2 and PC3/1 activity (Stengel and Tache 2010). During proteolytic 
processing of NUCB2 two inactive derivatives: nesfatin 2 and 3 are also created (Oh-
I et al. 2006). Interestingly, its sister protein nucleobindin-1 (NUCB1) is a precursor of 
another very weakly studied neuropeptide called nesfatin-1-like peptide (NLP) that 
also has anorexigenic properties in animals (Gawli et al. 2017). Nesfatin-1 has a 
highly conserved molecular structure which is characterized by a distinct sequence 
homology between mammals including human, and the lower vertebrate species 
(Gonzales et al. 2010). As the nesfatin-1 receptor is as yet unidentified it is 
impossible to target the neuropeptide signaling via pharmacomodulation. An 
autoradiographic receptor study has detected high 125I-nesfatin-1 signal in the 
paraventricular nucleus, neocortex, cerebellum and brainstem (Prinz et al. 2016). In 
the brain nesfatin-1 expressing neurons are localized mainly in the arcuate (ARC), 
paraventricular (PVN) and supraoptic (SON) nuclei as well as in the dorsomedial 
(DMH) and lateral hypothalamus (LHA) (Goebel et al. 2009). Embryological studies 
proved that they derived from a progenitor cell population with Developing Brain 
Homeobox 1 (Dbx-1) gene expression (Sokolowski et al. 2016). Nesfatin-1 is an 
anorexigenic factor, inducing satiety, and inhibiting food and water intake, it is 
assumed that the anorexigenic action of this peptide is performed mostly in the first 
three key regulatory hypothalamic centres. 
 
4.2. Animal studies 
 Several recently conducted studies suggest that acute restrain stress is one of 
the factors activating nesfatin PVN, SON, NTS and Edinger-Westphal nucleus (EW) 
neurons (Stengel et al., 2010a). Total adrenalectomy leads to increased mRNA 
NUCB2 expression in PVN, but i.v. nesfatin-1 injection causes an elevation of stress 
hormones: ACTH and corticosterone levels in serum (Konczol et al., 2010). Nesfatin-
1 seems also to contribute to generalized signs of stress; administration of this 
peptide into lateral ventricles of the rat brain causes elevation of blood pressure 
(Yosten and Samson 2010). It has been suggested that the pressor effects of 
centrally administered nesfatin-1 are also the result of stimulation of renal 
sympathetic nerves, mediated via melanocortin hypothalamic pathways (Tanida and 
Mori 2011). Furthermore, the expression of nesfatin-1 in raphe nuclei, locus 
coeruleus (LC) and EW neurons, in rats exposed to different stressors such as wrap 
restraint stress, abdominal surgery and lipopolysaccharide administration was 
increased. Nesfatin-1 activates stress-sensitive serotoninergic neurons of raphe 
nuclei, and noradrenergic LC neurons, that in turn stimulate CRF neurons in PVN, 
and finally activate the HPA axis. It has been known that the raphe nuclei and LC are 
also the key centres of serotoninergic and noradrenergic brain signaling systems, 
and their dysfunctions are closely correlated with pathogenesis of depression and 
anxiety disorders. At the present time, it seems probable that nesfatin-1 can play a 
hypothetical and nonspecific role in these mechanisms. Some authors suggest that 
nesfatin-1 induces anxiety or fear reactions and perhaps depressive reactions, via 
activation of melanocortin pathways, causing inhibition of GABA-ergic neurons or 
alternatively, through hyperpolarization of NPY neurons in the ARC (Bali et al. 2014, 
Emmerzaal and Kozicz 2013). 
Behavioural studies on male rats showed that intracerebroventricular injection 
of nesfatin-1 dose dependently shortened the time spent on the open arms of the 
EPM that is a reflection of its anxiogenic activity, increased the time spent freezing 
but decreased the food intake under an unfamiliar, potentially worrying environmental 
condition. Noteworthy, nesfatin-1 did not change any kinds of locomotor activity 
(Merali et al. 2008). Furthermore, an extended intraperitoneal nesfatin-1 
administration also promoted the anxiety-like behaviour in male rats and decreased 
the brain derived neurotrophic factor (BDNF) and phosphorylated ERK in the 
prefrontal cortex and hippocampus  (Ge et al. 2015). The aforementioned findings 
suggest a putative role of nesfatin-1 in the origin of anxiety and fear-related 
responses in animals. Another study reports that rats exposed to acute but not 
chronic stress showed increased NUCB2/nesfatin-1 and CRH mRNA expression in 
the hypothalamus.  Plasma nesfatin-1 and corticosterone levels were also elevated  
(Xu et al. 2015).Important recent evidence shows that the CRHR1 receptor  may be 
involved in the ERK1/2-dependent  mechanism of nesfatin-1 effect on synapsin 
action. Human neuroblastoma SH-SY5Y cells treated in culture with nesfatin-1 
upregulated  both mRNA and protein expressions of CRH and also increased the 
protein levels of p-ERK1/2 and synapsin I. These effects were abolished by 
CP376395, a selective antagonist of CRH type 1 receptor (CRHR1). Furthermore, the 
specific blocker of p-ERK1/2, PD98059 selectively reversed the nesfatin-1 induced 
elevation of synapsin I expression (Chen et al. 2017). 
Nesfatin-1 release from the  hypothalamic ARC neurons including 
POMC/CART cells inhibits the orexigenic NPY/AgRP cells directly (Fig.3.), causing 
their hyperpolarization through the ATP-dependent potassium channels Kir6.2. 
Glibenclamide, an antagonist of Kir6.2, relieves this effect that may support this 
mechanism of nesfatin-1 action. A suppression of orexigenic ARC neurons can play a 
key role in nesfatin-1 induced anorexia (Price and Samson, 2008). Noteworthy, the 
blockage of NPY/AgRP neurons can be reversed by pertussis toxin, suggesting that 
nesfatin-1 is also a ligand of a so far unidentified G-coupled receptor. The activation 
of this putative receptor leads to opening of the L and P/Q-type calcium channels, 
since the use of their selective inhibitors verapamil and -conotoxin results in 
removal of the nesfatin-1 dependent influx of Ca2+ ions (Brailoiu et al., 2007). 
Deacylated ghrelin can inhibit the ghrelin sensitive NPY/AgRP neurons by acting 
through nesfatin-1 releasing cells (Inhoff et al. 2008). Primary studies revealed that 
leptin did not modulate the NUCB2 and nesfatin-1 expression in the rat 
hypothalamus and in turn inhibition of nesfatinergic pathways did not affect leptin 
anorexigenic signaling (Oh et al. 2006). However, more recent evidence suggests 
that nesfatin-1 activity and NUCB2 mRNA expression in PVN neurons is directly 
upregulated by leptin. Two hours after injection of leptin to this hypothalamic nucleus 
significant increase of NUCB2 mRNA occurs (Darambazar et al. 2015). Noteworthy, 
the elevation of nesfatin-1 gene expression was connected with the light phase in 
normal individuals, while in Zucker-fatty rats with knock out leptin receptor this 
circadian pattern of changes is disturbed (Sedbazar et al. 2013). Peripherally 
administered bombesin and cholecystokinin (CCK-8S) can also activate nesfatin-1 
neurons (Engster et al. 2016, Noetzel et al. 2009). Conversely, POMC-derived-a-
MSH increased calcium concentration in the PVN nesfatin-1 (Sedbazar et al. 2014). 
Nesfatin-1 is a factor that significantly stimulates oxytocin secretion by magno- and 
parvocellular neurons (PVN) in rats. However, it has not been found that it causes the 
elevation of oxytocin concentration in serum (Yosten and Samson, 2010). Satiety, 
caused by central infusion of nesfatin-1 is relieved by administration of the CRF2 
receptor antagonist – astressin2-B (Yosten and Samson 2010). The melanocortin 
MC4 receptor in PVN plays a crucial role in the regulation of the eating process, and 
therefore, one may speculate that the nesfatin-1 neurons, displaying coexpression of 
oxytocin, vasopressin, MCH and CRF are the effectors in melanocortin signalization 
pathway (Kohno et al. 2008, Fort et al. 2008, Yosten and Samson, 2009). It has also 
been noted that the injection of a-MSH to the rat cerebral ventricles increases the 
expression of NUCB2 mRNA in the PVN neurons. This suggests that the cells which 
synthesize this peptide, act through the melanocortin receptors (Maejima et al., 
2009). Although the mechanisms of these actions are still unknown, the relevance of 
the proposed hypothesis is supported by the fact that changes in NUCB2 expression 
levels had not been reported after prior use of SHU9119, a selective antagonist of 
melanocortin MC3 and MC4 receptors (Brailoiu et al., 2007). There are also 
suggestions that nesfatin-1-expressing neurons may be sensitive to circulating 
oxytocin in rats. A number of nesfatin-1 cells in the ARC and PVN increased after 
intraperitoneal injection of oxytocin, while on the other hand central administration of 
antisense nesfatin-1 decreased the inhibitory effect of oxytocin on food intake (Saito 
et al. 2017). A recent study reported that intraperitoneal injection of cisplatin 
stimulated nesfatin-1 neurons in the hypothalamus and suppressed food intake in 
rats (Akiyama et al. 2017) which seems to be interesting from the oncological 
viewpoint. Direct injection of nesfatin-1 to the lateral ventricle of the rat brain caused 
a dose dependent suppression of consumatory behaviour. Extended infusion to the 
III-rd ventricle results in a significant reduction of body mass, and decrease in the 
amount of white adipose tissue. An intraperitoneal injection of nesfatin-1 induces in 
mice a 3- hour suppression of food intake, a subcutaneous administration induces 
the identical effect, and this anorexigenic action is maintained for 14 hours. Repeated 
intraperitoneal doses have substantially inhibited the increase of body mass, over a 
6-day period. Extended subcutaneous infusion of nesfatin-1 also caused a significant 
decrease of food intake in rats (Mortazavi et al. 2015).  It should be underlined that 
the peripheral nesfatin-1 doses required to depress food intake are approx. 1000-fold 
higher than those effective in the CNS. A serum level of nesfatin-1 is substantially 
decreased in state of starvation, and refeeding leads to its normalization. Nesfatin-1 
penetrates the blood-brain barrier which potentially creates a possibility for its 
therapeutic use. It appears that after reaching the hypothalamic centres, nesfatin-1 
will inhibit appetite and food intake. It has recently been noted that in humans the 
CSF/plasma nesfatin-1 ratio is significantly, negatively correlated with BMI (body 
mass index) and body mass that can suggest that nesfatin-1 is a protein-bound 
neuropeptide. A hypothesis was also proposed that dependent on  body mass 
changes,efficiency of  nesfatin-1 uptake by the CSF can be caused by saturation of 
its transporters (Pan et al. 2007). It also suggested that hypothalamic 
NUCB2/nesfatin-1 is involved in the hepatic insulin-dependent glucose homeostasis 
through activation of the mTOR-STAT3 signaling system (Wu et al. 2014). The 
activation of nesfatin-1 neurons in several rat brain nuclei under conditions of long-
term activity-based anorexia (ABA) was recently  studied with use of 
immunohistochemical methods (Scharner et al. 2017). The female individuals were 
divided into the following experimental goups: ABA, restricted feeding (RF), activity 
(AC) and ad libitum fed (AL). Interestingly, the number of nesfatin-1 immunopositive 
neurons in the PVN, ARC, DMH, locus coeruleus and in the rostral part of the 
nucleus of the solitary tract was increased in ABA group compared to AL and AC 
groups but not to RF rats. Furhermore, significantly more c-Fos and nesfatin-1 ir 
double-labeled cells were found in ABA animals compared to RF, AL and AC in the 
supraoptic nucleus and compared to AL and AC in the PVN, ARC, DMH, dorsal 
raphe nucleus and the rostral raphe pallidus. It should not be exluded that the 
observed changes of central nesfatin-1 immunoreactivity might play a potential role 
also in female patients suffered from AN. 
 
4.3. Human studies. 
Given the generally proven regularity that AN is often accompanied by anxiety 
and depressive-like behaviour (Lulé at al. 2014, Gauthier et al. 2014, Thornton et al. 
2011) we decided to discuss a putative involvement of nesfatin-1 in the origin of 
these disorders jointly.  This novel food intake inhibiting factor might be involved in 
the modulation of anxiety and in the central regulation of eating beaviour in AN 
(Hofmann et al. 2015a). 
In patients sufferring from major depressive disorder (MDD), a higher serum 
nesfatin-1 level has been revealed, compared to levels reported in a control 
population (Ari et al. 2011). This may be a proof of bidirectional permeability of the 
blood-brain barrier for nesfatin-1. The mechanism of this phenomenon is unknown 
due to a lack of information indicating which nesfatin-1 expressing cell populations of 
the brain are responsible for the increased neuropeptide secretion in patients with 
MDD. Moreover, it also cannot be excluded that the additional source of circulating 
nesfatin-1 may be secondarily activated by some cells, located outside of the CNS. A 
study performed by Bloem et al. (2011) has revealed that nesfatin-1/NUCB2 mRNA 
expression in the human Westphal-Edinger nucleus (EW) was significantly elevated 
in suicidal cases among males, whereas among females, this content was lower, 
compared to controls. Midbrain CART mRNA levels were in turn elevated in both 
male and female victims.  Noteworthy, the deceased individuals did not have 
diagnostically confirmed psychiatric disorders. This intriguing finding is the first to 
show sex-related changes in the neuropeptides levels in the brainstem of suicide 
victims. The colocalization of nesfatin-1/NUCB2 and CART in the EW was also 
found, suggesting the existence of potential  interplay between both neuropeptides in 
the brain. Thus, the possible  role of nesfatin-1 signaling in the pathogenesis of 
depressive-like and anxiety behaviour  should be taken into consideration.  
Despite the accumulating studies on novel neuropeptides the relationships 
between anxiety and nesfatin-1 action are understudied in humans.The clinical 
experiment carried out by Gunay et al. (2012) showed that male patients with 
generalize anxiety disorder had a decreased plasma level of nesfatin-1 than control 
groups. Another study aimed to find the potential sex-related correlations between 
serum nesfatin-1 levels and anxiety in obese patients and their changes during the 
treatment.  In women, at the beginning and during of therapy the nesfatin-1 level was 
positively correlated with anxiety scores. Conversely a distinct negative correlation 
occurred in men during the treatment. Interestingly, neither female nor male patients 
with improved anxiety scores showed significant fluctuations in plasma nesfatin-1 
levels. This finding suggests that women and men display an inverse relation 
between NUCB2/nesfatin-1 and anxiety. Females show positive but males negative 
correlation but this association was not statistically significant in men at the initial 
phase of treatment (Hofmann et al. 2015b). Noteworthy, no correlation was found 
between serum nesfatin-1 concentrations and BMI (Hofmann et al. 2015a). The same 
research team previously reported a positive correlation between plasma nesfatin-1 
levels and depression scores in obese females (Hofmann et al. 2013) that is in line 
with the evidence showing elevated neuropeptide concentrations in normal weight 
patients with depression (Ari et al. 2011).  
 The plasma nesfatin-1 levels were also measured in AN patients with low and 
high anxiety scores evaluated according to the GAD-7 protocol. In patients with high 
anxiety scores the elevated nesfatin-1 level was found suggesting a positive 
correlation between the GAD-7 value and neuropeptide concentration. Both 
depressiveness (PSQ-20) perceived stress (PHQ-9) and disordered eating (EDI-2)  
scales were not associated with nesfatin-1 but were increased in the high anxiety 
patients. Taken together, plasma nesfatin-1 levels correlate positively with perceived 
anxiety without any asssociations with the symptoms of eating disturbances 
(Hofmann et al. 2015a). The aforementioned clinical results may be compared with a 
recent study by Lu et al. (2017) revealed sex-related changes of orexin A and OX2R 
levels in the brain of depression patients. The orexin A immunoreactivity in the post 
mortem examined hypothalamus was significantly increased in depressive females 
but not in males in comparison to healthy controls.  Moreover in the anterior cingulate 
cortex of males who had committed suicide a significant increase of OX2R was found 
(Lu et al. 2017).  Due to highly anorexigenic properties of nesfatin-1, it seems justified 
to conduct further research studies analyzing its potential role in pathogenesis of 
psychogenic eating disorders. Recently, it has been noted that plasma nesfatin-1 
levels in patients suffering from restricting-type anorexia nervosa (AN-R) were 
significantly lower, compared with healthy controls. This may indicate a negative 
correlation with ghrelin and des-acyl ghrelin levels. In contrast, a positive correlation 
between nesfatin-1 levels and BMI was demonstrated (Ogiso et al., 2011).  An 
opposite phenomenon was displayed in healthy men, with normal body mass index, 
in whom the fasting nesfatin-1 concentration negatively correlated with their BMI 
(Tsuchiya et al., 2010). This observation was similar to the one reported in rats 
(Stengel et al., 2009). However, there is still no convincing evidence that this low 
nesfatin-1 level underlies anxiety disorders, often accompanying AN-R. On the other 
hand, it cannot be excluded that during periods of extreme starvation, even the 
decreased nesfatin-1 level may reduce anxiety or fear, and stimulate food-intake.  
 
5. Phoenixin in autonomic and mental functions 
 
Phoenixin (PNX) a newly identified, endogenous regulatory neuropeptide of the brain 
(Yosten et al. 2013) exists in two different, active molecular forms PNX-14 and PNX-
20 (Fig.1). Both of them are extremely conserved across vertebrate species, products 
of prohormone SMIM20 postranslational cleavage. The phoenixin was identified 
using a novel bioinformatic algorithm created by the Human Genome project that 
allows to predict previously unknown neuropeptides such as neuronostatin (Samson 
et al. 2008). According to this method some potential receptor molecules with a 
transmembrane domain are eliminated (SMART database) but putative proteins that 
contain signal peptides are included (SignalP database). In the next step, all 
sequences encoding known molecules were excluded. Finally, peptides with dibasic 
cleavage domains flanking a core region were taken into account using BioRegEx 
database and their highly conserved sequences were identified with NCBI BLAST. 
PNX may affect the pituitary gonadotropin release by modulation of GnRH-R receptor 
expression. Preliminary studies also suggested, that phoenixin sensitizes hypophysis 
to releasing factors rather than directly stimulates hormone exocytosis from pituitary 
cells (Yosten et al. 2013).  The presence of PNX was identified in the limited neural 
populations in the lateral hypothalamus, VMH, SON, PVN, ARC, anterior horns of 
spinal cord, spinal trigeminal and solitary tracts and sensory ganglia (Lyu et al. 2013). 
Surprisingly, a distinct assembly of phoenixin-expressing cells was recently found in 
the rat central amygdala (Prinz et al. 2017). The arcuate nucleus contains a 
population of kisspeptin neurons with PNX expression that send their efferents to the 
GnRH cells in the medial preoptic area (Gottsch et al. 2014). PNX may be therefore a 
novel hypothalamic regulatory factor that stimulates the action of pituitary 
gonadotopes. Hypothetically, PNX may also activate kisspeptin neurons through an 
autocrine manner and/or via connections with other PNX-expressing cells (Treen et 
al 2016). Noteworthy, a distinct majority of nesfatin neurons in the rat hypothalamic 
nuclei exhibits phoenixin expression, that may suggest an existence of potential so 
far unknown functional correlations between these neuropeptides in the brain (Pałasz 
et al. 2015). PNX is a ligand of metabotropic GPR173 receptor significantly 
expressed in both kisspeptin and GnRH neurons (Treen et al. 2016). GPR173 
alternatively known as SREB3 belongs to the superconserved receptor expressed in 
the brain (SREB) family, that has been found in the brain and ovaries and may play 
an important role in the regulation of the HPG axis (Matsumoto et al. 2005) Recent 
evidences suggest that GPR173 receptor in the hypothalamic neurons  acts via 
cAMP/protein kinase A pathway through CREB, and probably C/EBP-β and/or Oct-1 
to stimulate the kisspeptin-1 and GnRH expression. (Treen et al. 2016). Previous 
findings hypothesized, that PNX does acivate MAPK/ERK signaling pathway 
(personal communication). The selective modulators of GPR173 are yet to be 
unraveled that substantialy limits the range of pharmacological investigations dealing 
with PNX neurophysiology. It was also reported that PNX may prefentially inhibit 
visceral but not thermal pain. Recent evidence revealed that intracerebroventricular 
but not intraperitoneal infusion of PNX-14 during the subjective day increased  food 
intake in rats. This change was not connected with any significant alterations in motor 
function or grooming activity. The PNX administration during the dark phase did not 
affect  eating behaviour (Schalla et al. 2017). It may be therefore suggested that PNX 
is a new hypothalamic orexigenic neuropeptide being controlled by circadian 
rhythms. Moreover, these valuable results enable us to make the hypothesis that 
peripherally secreted PNX does not cross the blood barrier or does it to a minimal 
degree. One can therefore finally conclude that only brain-derived PNX can play a 
significant role in the central control of food intake. Noteworthy, an elevated plasma 
PNX-14 level in women with polycystic ovary syndrome (PCOS) suggests a potential 
involvement of PNX in the pathogenesis of this hormonally-related disease (Ullah et 
al. 2017). A valuable study by Jiang et al. (2015a) proved that PNX-14 acts as a 
potent anxiolytic factor in male mice when administered centrally. An infusion of PNX-
14 into the lateral ventricle or anterior hypothalamic area (AHA) but not into the 
amygdala evoked anxiolytic-like behaviour in the open field and elevated plus maze 
test in adult animals. Importantly, treatment with a selective GnRH receptor 
antagonist (cetrorelix) abolished the anxiolitic action of PNX-14. In turn, a blockage of 
oxytocin/vasopressin receptors by atosiban did not change this effect. It should be 
therefore accepted that PNX-14 generates its oxytocin-independent anxiolytic activity 
via the stimulation of GnRH signaling system in the anterior hypothalamus. A recent 
clinical investigation by Hofmann et al. (2017b) examined for the first time a 
relationship between peripheral phoenixin levels and anxiety in a large group (68) of 
obese psychometrically diagnosed (GAD-7) male in-patients. The levels of 
depression and perceived stress were also measured using PHQ-9 and PSQ-20 
scales respectively. The plasma phoenixin concentration was negatively correlated 
with anxiety scores, while any associations with other parameters were not detected.  
Since GnRH system may play a role in the regulation of learning and memory 
processes a possible effect of PNX-14 in these phenomena was examined using 
object recognition (NOR) and object location recognition (OLR) tasks. Intriguingly, an 
intracerebroventricular injection of PNX-14 immediately after testing significantly 
facilitated memory formation in rats. Furthermore, the memory retention was also 
extended under this experimental condition. The same changes occurred after direct 
infusion of PNX-14 into the hippocampus but they were inhibited by a selective GnRH 
antagonist (cetrorelix). It was also reported that central PNX-14 injection may 
decrease the memory impairment induced by the amyloid-β1-42 peptide and 
scopolamine suggesting that PNX-14 may be effective as a potential therapeutic in 
the treatment of Alzheimer׳s disease (Jiang et al. 2015b). A new study by Yuruyen et 
al. (2017) concerned with the aforementioned problem and examined for the first time 
the relationships between plasma PNX level and subjective memory complaints in 
geriatric patients with mild cognitive impairment (MCI). Interestingly, the mean serum 
PNX concentration was negatively correlated with logical memory. Decreased 
plasma PNX levels should be potentially taken into account in the initial stages of 
MCI as a putative predictive biological marker. Unexpectedly, PNX levels did not 
correlate with cognitive functions in patients with AD. To date, extremely little is 
known about PNX role in the higher mental functions, so the mechanism of its action 




6. Spexin as a potent anorexigenic factor 
 
Spexin (SPX) is a recently described neuropeptide, a transcript of the Ch12orf39 
gene which was discovered with bioinformatics tools (Mirabeau et al. 2007). SPX was 
identified using a hidden Markov model (HMM) based algorithm that integrates 
several neuropeptide sequence properties for the detection of new signaling 
molecules. Noteworthy, HMMs may applied to both gene prediction and protein 
domain analysis (Birney et al. 2004, Krogh et al. 1994). An HMM facilitates to find 
unknown protein sequence motifs, and it can also be used to determine whether a 
protein contains a specific domain. SPX has no structural similarities to known 
neuropeptides but it is phylogenetically highly conserved among the vertebrate 
species, rodent SPX differs from primate molecules by only one amino acid at the C-
terminal domain (Porzionato et al. 2010, Fig.1.). In the rat brain, many SPX-
expressing neural populations have been detected with the highest reaction in the 
hypothalamic paraventricular and supraoptic nuclei. SPX immunoreactivity has been 
also found in the hippocampus, amygdala, cerebellum and brainstem  (Porzionato et 
al. 2010). A recent study suggested that SPX is an alternative endogenous ligand for 
the GALR2/3 receptors, that exhibits even higher affinity toward GALR3 than galanin 
(Kim et al. 2014). The galanin receptors are considered as modulators of fear 
responses (Bailey et al. 2007, Lu et al. 2008). This anxiety behaviour was observed 
in GALR1 and GALR2 knock-out mice (Holmes et al. 2003), the GALR2-mediated 
effect is in turn distinctly different than GALR3 action, as selective GALR3  
antagonists decrease anxiety and promote depression-like behavior in rats (Swanson 
et al. 2005) SPX acting as GALR2/3 ligand should be theoretically evoked anxiolytic 
effects. Indeed, the SPX-like GALR2-specific agonist causes an acute anxiolytic 
profile in the elevated plus-maze (Reyes-Alcaraz et al. 2016). 
SPX has multiple physiological functions with studies in goldfish revealing the 
involvement of SPX in reproduction and food-intake regulation. Treatment of animals 
with SPX decreased the secretion of luteinizing hormone and also suppressed 
appetite. Brain injection of goldfish with SPX inhibited both basal and NPY- or orexin-
dependent consumatory behaviour and food intake (Wong et al. 2013). Recent 
findings also demonstrate a role for SPX in the control of cardiovascular/renal 
function and nociception (Porzionato et al. 2012), for instance SPX infusion to the rat 
brain ventricles decreased the heart rate without effecting blood pressure, but with an 
increase of renal  filtration rate (Toll et al. 2012). It also reported that SPX stimulated 
basal aldosterone secretion by adrenal endocrine cells in vitro. After long-term 
exposure of this culture to SPX a moderate increase in corticosterone secretion but a 
significant decrease of cell proliferation occured (Ruciński et al. 2010). Intriguing 
recent results published by Walewski et al. (2014) showed that SPX may be a potent 
anorexigenic factor involved in weight regulation, with a possible application for 
obesity therapy. Peripheral SPX injections caused a strong depression of food intake 
and significant reduction of body weight in both DIO mice and rats. No taste-aversive 
effects of SPX administration were reported. Interestingly, a negative relation 
between leptin and SPX levels in the plasma of obese and normal weight patients 
was also revealed suggesting that both neuropeptides may play antagonistic roles in 
the regulation of eating behaviour and energy expenditure. SPX may also be a fat-
expressed satiety factor and its gene was the most down-regulated in microarray 
assessment of human adipocytes (Walewski et al. 2010). A valuable piece of 
information about spexin physiology stems also from studies on a fish model. In 
goldfish an elevated plasma SPX level after eating was detected with simultaneous 
increase of SPX mRNA expression in the liver. The same effect on SPX mRNA 
concentration was also found in the liver and hypothalamus after intraperitoneal 
injection of glucose and insulin, respectively. Interstingly an insulin release triggered 
by glucose may stimulate SPX gene expression in the brain. Probably both central 
and peripheral effects of insulin on SPX gene expression in goldfish were mediated 
by insulin receptor and to a lesser degree by IGF-1 receptor coupled to mitogen-
activated protein kinases 3/6/p38, phosphatidylinositol 3-kinase/Akt/mammalian 
target of rapamycin but not 1/2/extracellular signal-regulated kinase 1/2 pathways. 
Insulin can therefore act as the postprandial signal linking food intake with SPX 
signaling system in lower vertebrates (Ma et al. 2017). A recent result corroborates a 
role of SPX as a metabolic biomarker of glucose control in humans. Clinical study by 
Hodges et al. (2017) examined the effect of obesity, type 2 diabetes and glucose 
administration on serum SPX concentrations in adolescents of both sexes. 
Unexpectedly, the median fasting SPX levels were unchanged between the groups. 
Moreover, they were also not correlated with biochemical parameters and body 
composition. Judging by the potent anorexigenic properties of SPX it should not be 
excluded that a putative excess in the hypothalamic SPX signaling may be 
associated with the origin of AN. This interesting possibility certainly requires further 
basic and clinical studies. 
 
7. A hypothetical nesfatin-1 and phoenixin mode of action in the mechanism of 
anxiety and anorexia nervosa. 
In spite of the ongoing research on nesfatin-1 physiology its role in the 
mechanism of anxiety is as yet not explained. Taking into account that hypothalamus, 
a structure especially rich in peptidergic neurons is the main area of nesfatin-1 action 
several hypotheses can be formulated. The first one suggests a direct effect of 
nesfatin-1 on the CRF synthesis and release that may control the HPA axis activation 
(Merali et al. 2008). The crucial position of CRF in the central circuits regulating 
anxiety, fear reactions and stress responses is generally accepted (Borrow et al. 
2016, Bale and Vale 2004). Patients suffering from AN show both extremely reduced 
food intake and increased physical activity. According to anxiety-related model of this 
disorder, these patients have highly elevated CRH and glucocorticoid release during 
eating that reflects the activation of hypothalamic-pituitary-adrenal (HPA) axis 
(Connan et al. 2007). Moreover, food intake stimulates CCK secretion, generating 
satiety and simultaneously activating CRH release that causes an elevated anxiety 
responses and inhibited consumatory behaviour. Given both high CRF-nesfatin-1 
coexpression and numerous paracrine interconnections between nesfatin-1 and CRF 
cells this possibility seems to be especially reliable (Fig.2.). Molecular studies also 
prove that PVN neurons release nesfatin-1 from secretory vesicles (Maejima et al. 
2009). CRF-expressing cells may be sensitive to nesfatin-1, however its receptor is 
still unknown therefore the precise mechanism of nesfatin-1 action is not clear. It 
should be taken into account that CRF neurons in the PVN differ both in their 
response to paracrine neuropeptide release and their influence on target neuronal 
populations. (Dabrowska et al. 2013). The potential anxiogenic effect of nesfatin-1 
may be a result of putative G-coupled receptor stimulation and activation of 
intracellular signaling cascades that enable the CRF release into the median 
eminence. The increased level of calcium in the CRF neurons isolated from rat PVN 
after exposure to nesfatin-1 supports this hypothesis. Moreover, central injection of 
nesfatin-1 without additional stressogenic stimuli causes elevation of circulating 
ACTH and cortiosterone levels (Yoshida et al. 2010). Interestingly, nesfatin-1 
sensitive noradrenergic and serotoninergic neurons in the respectively locus 
coeruleus and dorsal raphe send their projections to CRF neurons in PVN that may 
stimulate HPA axis in an alternative way (Cunningham and Sawchenko 1988).  
Taken together, only centrally expressed nesfatin-1 is involved in the anxiety 
generation and nesfatinergic neurons both in the hypothalamus and brainstem may 
evoke early phase fear responses through the stimulation of CRF and aminergic 
neurons. Regardless of direct or indirect stimulation of CRF neurons by nesfatin-1, 
the final physiological outcome of neuropeptide action depends on the type of CRF 
receptor which will be activated. It should not be therefore excluded that nesfatin-1 
may also affect the synthesis and release of urocortins at the level of hypothalamic 
circuits. On the other hand, it should be suggested that nesfatin-1 may be an 
alternative ligand of CRF receptors. Additionally, nesfatin-1 signalling may also play a 
role in the mechanism of visceral hypersensitivity by modulation of CRF/CRF1 
system  (Jia et al. 2013). The influence of nesfatin-1 on CRF signaling may also take 
place outside thehypothalamus, especially in the amygdala, where distinct NUCB2 
expression  occurs (Goebel et al. 2009). There is a hypothesis suggesting that 
stress-related anxiety can be regulated by different groups of CRF neurons in the 
amygdaloid complex and BNST (Walker 2009). It should not be excluded that 
nesfatin-1 coexpressing CRF neurons belong to one of these cellular populations. A 
study by Regev et al. (2011) revealed that CRF ovexpression in the central nucleus 
of amygdala (CeA) caused decreased stress-dependent anxiety symptoms in rats. 
Conversely, another report showed elevated level of anxiety in rats with excess CRF 
expression in CeA and increased in the PVN (Shepard and Myers 2008). Nesfatin-1 
released in the CeA may probably affect the anxiety responses through modulation of 
the CRF exocytosis from local neurons. A recent advanced study with use of 
retrograde tracing showed that the nesfatin-1 neurons in the CA1 region of 
hippocampus send their stimulatory projections to the ventromedial hypothalamus. 
Furthermore, an electrical stimulation of these cells evoked excitation of the VMH 
neurons. Nesfatin-1 injection to VMH decreases the activity of gastric distension 
responsive neurons through the modulation of CRF signaling circuit (Feng et al. 
2017). One can therefore hypothesize that nesfatin-1 signalling may connect the 
hypothalamic and limbic structures responsible for both anxiety responses and 
consumatory behaviour. 
The BDNF pathway may also be a potential target for nesfatin-1 action in the 
central mechanisms of anxiety. As previously mentioned long-term intraperitoneal 
injection of nesfatin-1 decreased BNDF protein expression in the rat hippocampus 
and prefrontal cortex and exerted anxiety-like behaviour (Ge et al. 2015).  It may 
support the reports suggesting an involvement of BDNF in the pathogenesis of 
anxiety and depression (Janke et al. 2015, Suliman et al. 2013). 
As previously mentioned the nesfatin-1 neurons, may act through the 
melanocortin receptors (Maejima et al., 2009). It suggests that the melanocortin 
signaling, both hypothalamic and limbic, may also be an alternative target for 
nesfatin-1 action in the brain mechanisms of anxiety. The melanocortin receptors, 
especially MC4R, which is highly expressed in brain, may play crucial roles in the 
regulation of stress and anxiety reactions (Chaki and Okubo 2007). A recent study 
proved that the anxiogenic action of another central neuropeptide PACAP was 
dependent on MC4R stimulation in the rat CeA (Iemolo et al. 2016). Moreover, 
activating MC4R in the medial amygdala (MeA) exerted anxiogenic and anorexigenic 
effects with a stimulation of the HPA axis in rats. Blocking MC4R in the MeA 
abolished such restraint stress-induced phenomena (Liu et al. 2013). 
The mechanism of adaptating food intake to energy expenditure as well as 
appropriate balance of both orexi- and anorexigenic hypothalamic neuropeptides are 
strongly altered in patients with AN. In this case the activity of anorexigenic 
POMC/CART, CRF, CCK-8S and oxytocin neurons in ARC/PVN may be 
pathologically overstimulated by nesfatin-1 and probably spexin (Fig.3.). Phoenixin 
seems to be in turn an orexigenic factor (Schalla et al. 2017). Food intake promoting 
AgRP/NPY, MCH, 26RFa and orexin neurons can be in turn blocked by the same 
regulatory neuropeptides (Price et al. 2008) but the receptor mechanisms of their 
actions are so far unknown. Since the brain derived neurotrophic factor (BDNF) is a 
potent anorexigenic factor involved in the pathogenesis of AN (Monteleone and Maj 
2013, Rios 2013), a potential influence of nesfatin-1 on its signaling pathway may be 
another possible strategy in the food intake depression in the course of this disorder. 
As well as nesfatin-1, the BDNF level as well as nesfatin-1 is strictly related to both 
energy equilibrium and reproductive phase. Nesfatin-1 administration decreased the 
BNDF expression in the rat brain (Ge et  al. 2015) however, the nature of the 
relationships between these two neuropepetides in the context of eating behaviors in 
humans is not yet clarified. It was found that patients with active restricting AN had 
lower serum BDNF levels than healthy controls (Brandys et al. 2011). Some previous 
genetic studies do also suggest that the BDNF gene may be involved in the 
development of AN (Ribases et al. 2005). The plasma BDNF levels were increased in 
patients with binge-eating/purging type AN  when compared to restricting type AN 
individuals (Eddy et al.2015). Another finding reported that normal-weight women 
with bulimia nervosa had increased serum BDNF levels compared with AN patients 
(Saito et al. 2009). The plasma BDNF levels in patients with AN undergo changes in 
the course of disorder. For instance, serum BDNF levels in women recovered from 
AN was higher in comparison to acutely underweight AN patients and had a 
tendency to increase with weight gain. Noteworthy, in AN but not healthy female 
controls, BDNF concentrations were inversely correlated with psychomotor activation 
(Zwipp et al. 2014). One can postulate, that nesfatinergic projections from ARC to 
VMH or/and local nesfatin-1 neurons in VMH may stimulate the BDNF synthesis and 
exocytosis that causes extended inhibition of food intake during AN, although the 
receptor mechanism of this effect remains unknown. Interestingly, the regulation of 
BNDF expression in the rat VMH seems to be sex-dependent. It was reported that 
fasted males but not females showed decreased BDNF level in the VMH in 
comparison to the control fed individuals following 24-hour food restriction.  In male  
high fat diet (HFD) obese and HFD-PF normal weight rats a lower BDNF expression 
compared with low fat diet (LFD) males occurred, suggesting  that suppressed BDNF 
signaling was associated with a fat-rich diet consumption instead of increased 
adiposity. Noteworthy, decreased BDNF expression during HFD may reinforce the 
eating behaviour and promotes the obesity in male animals. Conversely, 
hypothalamic  BDNF level in females remains stable even in condition of the severe 
energy imbalance. (Liu et al. 2014). Despite of the aforementioned findings a recent 
evidence does not recommend BDNF as a reliable biomarker in women with recovery 
from AN because an inverse significant correlation between plasma BDNF and 
anxiety occured only in healthy controls (Kawada 2017).  
Eating behaviour is controlled intimately by complex brain mechanisms of food 
reward, whether those signaling circuits act in normal or disturbed modes. To date it 
is not clarified whether the restricted pattern of food intake in AN are caused by 
structurally visible injuries in brain reward centres including nesfatin-1 neurons. A 
possible pharmacological treatment of those distorted pathways with drugs that affect 
reward-related neuronal assemblies in VTA or NAc still remains a hypothetical 
strategy. Moreover, it is not yet definitely proven whether any causes of AN are 
essentially dependent on brain reward system and how brain substrates of food 
reward relate to eating disorders. Nonetheless, it should be taken into account that 
mesolimbic dopamine and opiod systems that form hedonic “wanting-liking” brain 
hotspots may be involved in the pathogenesis of AN and other eating disorders 
(Castro and Berridge 2014). Those mechanisms might contribute to generating 
obsessive dreads e.g.  a persistent and compulsive focus on remaining extremely 
thin (Faure et al. 2008). The results published by Chen et al. (2015b) shed a new 
intriguing light on the hypothesis of nesfatin-1 role in the origin of AN suggesting its 
direct action on the dopaminergic reward circuits. Targeted nesfatin-1 injection to the 
ventral tegmental area (VTA) strongly decreased both the food consumption and 
dopamine release in the NAc. Nesfatin-1 effect on VTA seems to analogous to the 
leptin but different than ghrelin action (Hommel et al. 2006, Abizaid et al. 2006) It can 
be therefore possible that nesfatin-1 neurons in the lateral amygdala send their 
inhibitory efferents to the VTA neurons that evoke the anorexigenic effect. The 
nesfatin-1 mode of action in the reward circuits may resemble the effect of oxytocin at 
the NAc, while its injection to this structure caused a significant depression of food 
intake in rats (Herisson et al. 2016). It should be not excluded that the food intake 
restricting action of nesfatin-1 in AN may be initiated by the release of the 
endogenous anorexigenic factor GLP-1 into the hypothalamus. The GLP-1 neurons 
in the rat nucleus of solitary tract (NTS) send their long stimulatory projections to the 
CRF and nesfatin-1 cells in the PVN. GLP-1 administered in vitro evokes the calcium 
signaling cascade in the nesfatin-1 neurons isolated from PVN. Interestingly, precise 
injection of a GLP-1 receptor antagonist exendin (9-39) to the PVN  increased food 
intake (Katsurada et al. 2014). We realize that our hypothetic model may be 
considered a bit preliminary or even controversial.  Indeed, some of the data are 
purely correlational e.g. measurements of plasma neuropeptide levels, whereas other 
ones such as testing sufficiency or necessity of neuropeptide signaling are direct 
tests of involvement.  Unquestionably, a comparative degree of interpretative weight 
to each of these types of results should be placed cautiously.  It is also difficult to 
determine what are the actual sources of circulating neuropeptides (brain, peripheral 
nerves and ganglia or even endocrine cells) and what do plasma levels tell us about 
signaling actions within specific neural circuits in the brain. It should be taken into 
consideration that it is not absolutely clear whether the correlational data warrant the 
high level of interpretive emphasis. Despite the aforementioned limitations and 
doubts we are convinced that our original hypothesis may open a new chapter in the 
discussion of the peptidergic signaling in anxiety and anorexia nervosa.  
 
 
8. Kisspeptin in anxiety responses, depression and anorexia nervosa 
 
 
Kisspeptin, a C-terminally amidated neuropeptide and endogenous ligand of 
metabotropic Kiss1R (GPRS54) receptor plays an essential role in the hypophyseal 
regulation of the ovarian cycle (Constantin 2017, Navarro et al. 2015). The core 
molecule kisspeptin-54 is proteolytically cleaved into several smaller peptides 
kisspeptin-13 and 14 (Fig.1.). The majority of kisspeptin neurons are located in the 
hypothalamic ARC and anteroventral periventricular (AVPV) nuclei (Mikkelsen et al. 
2009)  Kisspeptin regulates the gonadotropin releasing hormone (GnRH)  synthesis 
in the hypothalamic neurons via stimulation of their firing and depolarization (Quaynor 
et al. 2007). The Kiss-1 gene expression in the hypothalamic nuclei is strictly 
controlled by circulating sex steroids (Navarro et al. 2004). Recent studies showed 
that mice with deletion of Kiss-1 gene in the GnRH neurons manifested disturbed 
sexual differentiation at the level of brain structures (Clarkson et al. 2014).  
Kisspeptin decreases food intake and may be therefore identified as the next 
hypothalamic anorexigenic factor (De Bond and Smith 2014, Stengel and Tache 
2011). Importantly, kisspeptin neurons send axonal projections to key regulatory 
neurons in the arcuate nucleus (Hrabovszky 2014). These efferents may directly 
stimulate POMC/CART and indirectly inhibit NPY/AgRP cells through enforced of 
GABA-ergic transmission (Fu et al. 2010).  
Kiss-1 mRNA expression was identified in the hippocampus, where it is about 
5-100 times weaker than in the hypothalamus (Arai and Orwig 2008). It is known, that 
some neuropeptides e.g. NPY and somatostatin affect the plasticity and excitability of 
hippocampal neurons (Baratta et al. 2002). This kisspeptin mode of action seems to 
be unique, because this neuropeptide increases stimulatory responses of neurons 
via modulation of postsynaptic signaling (Arai et al. 2009). Kisspeptin facilitates 
hippocampal synaptic transmission by activation of MAP kinase (MAPK) pathway in 
the granular cells of dentate gyrus. Perhaps this regulatory system plays so far 
unknown role in the mechanisms of learning and also in the pathogenesis of 
epilepsy. Kisspeptin and Kiss1R expressing neurons were recently identified also in 
the rat posterodorsal subnucleus of the medial amygdala (MePD) There are justified 
suggestions that kisspeptin in the MePD may affect male sexual behavior. Direct 
bilateral infusion of kisspeptin-10 to the MePD caused multiple erections, an effect 
connected with Kiss1 receptor activation, because Kiss1R antagonist abolished this 
physiological reaction. Conversely, an intracerebroventricular injection of kisspepetin 
did not exert any penile stimulation in rats. Interstingly enough, the kisspeptin 
increased plasma LH levels to comparable value when infused into both MePD and 
lateral ventricle (Pineda et al. 2017, Gresham et al. 2016). Fluorescent studies using 
retro- and anterograde tracers, and viral transfection systems in wild-type and 
transgenic rodents revealed the presence of reciprocal connections between the 
kisspeptin neurons in the accessory olfactory bulb and amygdala. The kisspeptin 
neurons may inhibit the mitral cells in the accessory olfactory bulb. Noteworthy, 
kisspeptin neurons in the amygdala send their efferents to GnRH neurons in the 
hypothalamic preoptic area and they are probably innervated by vasopressinergic 
and dopaminergic neurons. Interestingly, peripheral kisspeptin administration 
significantly supressed signal intensity in the rat amygdala but  increased LH 
secretion in rodents. Moreover, a direct kisspeptin injection into the medial amygdala 
(MeA) caused an elevation of LH release.  Conversely, an inhibition of amygdalar 
kisspeptin signaling by targeted injecting of selective Kiss1 antagonist (peptide-234) 
generally depressed LH signaling. Taken together, this may prove that the kisspeptin 
regulatory system within the amygdala affects gonadotropin release and pulsatility. 
Furthermore, kisspeptin may be consider as the pivotal regulator of reproductive 
processes, connecting limbic centres with the hypothalamic GnRH neurons  
(Comninos et al. 2016). In the light of aforementioned information it has to be 
especially emphasized that Kiss-1 gene expression in both hippocampus and 
amygdala are dependent on the concentrations of circulating estrogens and 
progesterone (Cao and Patisaul 2013, Kim et al. 2011, Arai 2009). Behavioural 
studies revealed the anxiogenic effect of centrally injected kisspeptin-13 in rats, a 
neuropeptide administration caused a significant preference for the close arms in the 
EPM test (Csabafi et al. 2013). It suggests that kisspeptin stimulates stress-related 
CRF and AVP neurons both in the HPA axis in the amygdala (Pineda, et al. 2017). 
Kisspeptin is also considered as the novel endogenous antidepressant. Animal 
studies with modified forced swimming test (FST) revealing that kisspeptin-13 may 
reverse the immobility, climbing and swimming times in rats that may support this 
suggestion. Interstingly, the selective antagonists of (2)-adrenergic and 5-HT(2) 
serotonin receptors (phenoxybenzamine, yohimbine and cyproheptadine) abolished 
the behavioural effects of kisspeptin-13. It may prove, that antidepressant-like 
properties of kisspeptin-13 are mediated via interaction with the adrenergic and 
serotoninergic signaling pathways (Tanaka et al. 2013). Because the food intake-
regulatory neuropeptides may affect physical activity Hofmann et al. (2017a) 
examined potential relationship between the exercises  and plasma levels of  several 
regulatory factors including kisspeptin in females with AN. Additionally, associations 
with psychometric parameters: (PHQ-9), anxiety (GAD-7), perceived stress (PSQ-20) 
and disordered eating (EDI-2) and body composition were measured. Women 
showed disparate forms of physical activity revealed  a negative correlation with 
kisspeptin but positive association with ghrelin level. Interestingly no signifant 
correlations occured between intensive exercise and orexin-A, FGF-21 and R-
spondin-1 concentrations. There was also a positive association between kisspeptin 
level and BMI but negative with the interpersonal distrust subscale of the EDI-2. 
Taken together, depression, anxiety, and perceived stress were not correlated with 
serum kisspeptin level in AN. Kisspeptin seems to be inversely, but ghrelin positively, 
associated with physical activity in AN suggesting a potential role of these 
neuropeptides in the regulation of motor functions  in AN. (Hoffman 2017a).  A recent 
study by Bacopoulou et al. (2017) examined the serum kisspeptin levels in 
adolescent  females with typical and atypical AN. Atypical AN is a less severe eating 
disorder that does not met all diagnostic criteria for AN. Interestingly, the kisspeptin 
concentrations were lower in women with typical AN and higher in patients with 
atypical one. An increase of kisspeptin levels in the women with atypical AN whose 
ovarian activity weakened might have been caused by kisspeptin secretion in an 
effort to maintain menstruation. An excess of kisspeptin released by hypothalamic 
centres might have caused in a depletion of the neuropeptide reserve and thus in no 
further elevation in kisspeptin levels, as typical AN along with amenorrhea became 
physiologically determined. Since kisspeptin regulates the GnRH-dependent LH 
release the females with typical AN manifested lower LH plasma levels compared to 
healthy participants. Additionally, the plasma kisspeptin levels were negatively 
correlated with BMI in the patients with typical AN. 
 
9. Sex differences in nesfatin-1, phoenixin and kisspeptin signaling. 
 
A number of aforementioned recently published clinical studies revealed certain 
sex-related differences in plasma nesfatin-1, phoenixin and kisspeptin levels in 
various groups of patients suffered from AN, anxiety and obesity (Fig. 4.). The 
nesfatin-1 concentration was decreased in females with AN but increased when the 
women suffered from AN with anxiety symptoms (Ogiso et al. 2011, Hofmann et al. 
2015a). In male anxiety patients the serum nesfatin-1 level was lower when 
compared to controls (Gunay et al. 2012). Also phoenixin level was decreased in 
overweight men with anxiety (Hofmann et al. 2017a). Obese men showed negative 
but women positive correlation between nesfatin-1 levels and anxiety scores 
(Hofmann et al. 2015b, 2013). The serum kisspeptin level was increased in woman 
with atypical but decreased in patiens with typical symptoms of AN (Bacopoulou et al. 
2017). Additionally, both females and males with mild cognitive impairment had 
depressed levels of phoenixin (Yuruyen et al. 2017). Although these results are still 
rather difficult to interpret some hypothetical explanations can be formulated. First of 
all, it has to be emphasized that women reveal in general higher plasma nesfatin-1 
levels than men (Bergmann et al. 2015, Feijoo-Bandin et al. 2013).  Furthermore, due 
to a distinct prevalence of anxiety and depression in women compared to men 
(Gorman et al. 2006, Kuehner 2003), a potential sex-specific modulation of 
nesfatinergic and/or phoenixinergic signaling in the stress and fear responses seems 
to be especially interesting. An unusual report revealing the sex-related associations 
between plasma nesfatin-1 level and incidences of suicidal behaviour can support 
this point of view (Bloem et al. 2012). Since nesfatin-1, phoenixin and kisspeptin are 
involved in reproductive processes acting as gonadotropic axis stimulators their 
differential regulation may be related to sex steroid activity (Garcia-Galliano and 
Tena-Sempere 2013). Interestingly, NUCB2/nesfatin-1 expression in the pituitary 
gland of female rats is regulated by the ovarian 17β-estradiol and progesterone 
(Chung et al. 2015). In turn, in the male mice hypophyseal but not hypothalamic 
NUCB2 mRNA expression was depressed after castration (Seon et al. 2017). In 
these animals the NUCB2 mRNA level in the adenohypohysis was increased after 
testosterone administration. Conversely, the NUCB2 mRNA expression in the 
hypothalamus was significantly decreased after hormone treatment. The NUCB2 
mRNA expression in isolated hypothalamic cell culture was also significantly 
decreased with testosterone. An inverse effect occured with the same treatment in 
pituitary cells in vitro. Taken together, it suggests that sex steroids may affect the 
NUCB2 mRNA signaling in the rat HPG axis (Seon et al. 2017). This hypothesis is 
also supported by a report showing that testosterone increased NUCB2/nesfatin-1 
mRNA and protein expression in murine hypothalamic (GT-1-7) and pituitary (LT2) 
cells in vitro.  Interstingly, 17β-estradiol did so only in the hypohyseal cell culture. 
Kisspeptin and GnRH modulate central NUCB2/nesfatin-1 signalling,   treatment with 
kisspeptin caused an elevation of NUCB2/nesfatin-1 mRNA and protein expression in 
hypothalamic cells. Nesfatin-1 in turn increased GnRH and Kiss1R protein 
expression in both studied cells (Hatef and Uniappan 2017).  It should not be 
excluded, that some female hormonally dependent anxiety-like neuropsychiatric 
disturbances such as postpartum depression and premenstrual dysphoria may be 
related to some impairment of the nesfatin-1/kisspeptin regulatory system in the brain 
(Miller 2002, Noble 2005). Since brain nesfatin-1 and kisspeptin actions are CRF-
related a study showing that long-term treatment of adolescent female mice with 
androgenic steroids enhanced anxiety via increased CRF signaling of CeA efferents 
seems to be especially interesting (Costine et al. 2010). There are intriguing 
hypothesis suggesting that gender may affect differentially the activity of the CeA and 
PVN in rats. Electric shock increased CRF mRNA level in the CeA in both sexes, with 
higher amplitude in females in proestrus than in males. Conversely, psychological 
stress augmented amygdalar CRF mRNA expression only in male individuals.  A 
conclusion that hypothalamic CRF gene expression in the PVN is related to 
psychological stressors only in females may be a key point to explain of the 
neurochemical pathways underlying the sex-differential mechanism of AN (Iwasaki-
Sekino et al. 2009). Both nesfatin-1 and kisspeptin neurons are considered as 
sensitive to circulating sex hormones thus generally anxiogenic effect of ERα as well 
as anxiolytic action of ERβ may be potentially associated with their influence on 
anxiety-related hypothalamic peptidergic systems including nesfatin-1 and kisspeptin 
circuits (Borrow and Handa 2017). A study suggesting an 
oxytocin in the HPA-dependent generation of anxiety may support this hypothesis 
(Kudwa et al. 2014). Undoubtedly, a number of further studies are required to 
elucidate the potential sex-related associations of the newly identified neuropeptides 
and anxiety in the context of eating disorders. 
 
10. Concluding remarks 
 
Recently identified neuropeptides nesfatin-1, phoenixin, spexin and kisspeptin are 
characterized by a broad spectrum of sex-dependent regulatory activity in the brain. 
Accumulating evidence  considers them as novel and potentially  important factors 
involved in the pathogenesis of several mental disorders. It should not be therefore 
excluded that the putative pharmacomodulation of neuropeptide signaling may be 
potentially helpful in the future treatment of certain neuropsychiatric and metabolic 
disorders including anxiety and anorexia nervosa. Undoubtedly, more advanced 
investigations on this field merits special attention. Although the outcome of some 
basic and clinical studies seems to be encouraging, any possible applications of the 
aforementioned neuropeptides as well as their agonist and antagonists still remain in 
the area of speculation. Nonetheless, intensive searching for the selective 
modulators of their known receptors may contribute to opening of a promising 
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Fig. 2. An outline potential involvement of nesfatin-1 and kisspeptin in the 
mechanism of anxiety. Nesfatin-1 and kisspeptin neurons activate the synthesis and 
release of CRF both in the hypothalamus and central amygdala. The physiological 
outcome of neuropeptides action depends on the type of CRF receptor which will be 
stimulated. The CRF binding to CRF1 receptor exerts anxiogenic effects, whereas 
CRF2 receptor activation leads to anxiolytic effects. The melanocortin circuits, both 
hypothalamic and limbic, may also be a target for nesfatin-1 action in the central 
mechanisms of anxiety. Nesfatin-1 and kisspeptin released in the central amygdala 
may probably affect the anxiety responses through modulation of the CRF release 
from local neurons. A group of nesfatin-1 neurons in the CA1 region of hippocampus 
send their stimulatory projections to BDNF cells in the ventromedial hypothalamus 
 
Fig. 3. A hypothetical model of nesfatin-1, phoenixin, spexin and kisspeptin 
roles in the modulation of orexigenic pathways that activate reward system in 
anorexia nervosa. Extremely restricted food intake in AN stimulate the neuronal 
populations in the lateral hypothalamus (LHA) that will release a set of orexigenic 
neuropeptides (orexins, MCH and 26RFa) in the ventral tegmental area (VTA). These 
factors increase the dopamine exocytosis in the nucleus accumbens. In the course of 
AN, the activation of the reward circuits causes perisistent food aversion associated 
with elevated anxiety that will, in turn, reinforce the fasting behaviour. An important 
supporting roles in the mechanism of this reinforcement may play the newly found 
hypothalamic neuropeptides. An excess of nesfatin-1 may strongly inhibit orexigenic 
NPY/AgRP neurons but stimulate anorexigenic POMC/CART and kisspeptin neurons 
in ARC. The nesfatinergic projections can also directly stimulate anorexigenic CRF 
neurons in PVN and block the aforementioned feeding promoting cells in LH. 
Hypothalamic spexin may additionally activate the POMC/CART and probably 
oxytocin cells through the galanin Gal2/3 receptors. Conversely, PNX seems to 
stimulate the main orexigenic NPY/AgRP cells probably via GPR173 receptor, 
antagonizing the nesfatin-1 and spexin effects. Kisspeptin may also activate 
anorexigenic POMC/CART neurons via Kiss-1 receptor. 
 
 
Fig 4. Sex-related changes in the plasma nesfatin-1, phoenixin and kisspeptin 
levels in patients with diverse neuropsychiatric disorders. AN, anorexia nervosa; 
AN(A), typical AN; AN(A), atypical AN; MCI, mild cognitive impairment; Ob, obesity. 
